TLDR Blocking the CXCL12–CXCR4 axis may help treat hair loss in alopecia.
The CXCL12–CXCR4 axis plays a dual role in hair follicle biology, promoting hair regeneration under normal conditions but driving hair loss in alopecia, particularly in androgenetic alopecia (AGA) and alopecia areata (AA). In these conditions, CXCL12–CXCR4 signaling contributes to a fibroimmune microenvironment that leads to dermal fibrosis, chronic inflammation, and hair follicle miniaturization. The expression of CXCR4 is mainly found on pro-inflammatory macrophages and dermal papilla cells in diseased scalps, linking these cells to hair follicle damage. While regulatory T cells (Tregs) express CXCR4, their role in hair growth is minor compared to the pathological signals in alopecia. Therapeutically, blocking the CXCL12–CXCR4 axis has shown promise in reversing fibrosis, reducing immune cell accumulation, restoring dermal papilla cell function, and stimulating hair regrowth in AGA and AA models. The study highlights the importance of understanding the cellular sources and pathogenic roles of CXCL12–CXCR4 signaling in alopecia and the potential of targeting this axis as a treatment strategy.
October 2025 in “Cell Reports” Regulatory T cells help hair growth by using the Cxcr4-Cxcl12 pathway.
July 2025 in “International Journal of Molecular Sciences” Blocking CXCL12 can reverse hair loss and fibrosis in androgenetic alopecia.
4 citations
,
June 2025 in “Cell Reports” Clonally expanded CD8+ T cells cause alopecia areata.
December 2024 in “International Journal of Molecular Sciences” Targeting CXCL12 may help treat hair loss caused by androgens.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
January 2024 in “International Journal of Molecular Sciences” Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
23 citations
,
July 2023 in “Proceedings of the National Academy of Sciences” CD8+ T cells drive alopecia areata, while regulatory T cells are protective.
April 2022 in “Biomedicine & Pharmacotherapy” CXCL12 protein slows down hair growth through its receptor CXCR4. Blocking this can potentially increase hair growth.
27 citations
,
August 2021 in “Journal of Autoimmunity” Human dermal γδT-cells respond to stress in hair follicles, contributing to hair loss.
23 citations
,
September 2020 in “Journal of Dermatological Science” Targeting Vδ1+T-cells may help treat alopecia areata.
12 citations
,
December 2019 in “International Journal of Molecular Medicine” Stem cells from umbilical cord blood may prevent hair loss caused by certain medications.